Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ:KRMD) (“KORU Medical” or the “Company”) today announced that Don Pettigrew, President & CEO, will ring the Nasdaq Closing Bell on Wednesday, February 12, 2020 at 4:00 pm ET.

“We are honored to ring the closing bell in celebration of our recent uplisting to Nasdaq, our corporate re-branding to KORU Medical Systems, and our position as a market leader of innovative and easy-to-use specialty infusion devices,” said Mr. Pettigrew. “We appreciate the support of our customers, industry partners, shareholders, employees, and board members, and remain focused on providing new life and new beginnings to patients around the world who use KORU Medical’s integrated Freedom Syringe Infusion System. We continue to look forward to our future with confidence.”

About KORU Medical Systems
KORU Medical Systems develops, manufactures and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.

Forward-Looking Statements
The statements contained herein include prospects, statements of future expectations and other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: introduction of competitive products; availability of insurance reimbursement; changes in U.S. Food and Drug Administration regulations; changes to health care policies; success of our research and development efforts; our ability to raise capital if or when needed; acceptance of and demand for new and existing products; expanded market acceptance of the FREEDOM Syringe Infusion System; our ability to obtain required governmental approvals; success in enforcing and obtaining patents; continued performance by principal suppliers; continued customer preference to work through distributors; continued service of key personnel and attracting and maintaining new personnel; the costs, duration and ultimate outcome of litigation; and general economic and business conditions. These and other risks are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, which filings are available from the SEC and the Company’s website. The Company undertakes no obligation to update any forward-looking statements.

Contacts

The Equity Group Inc.
Devin Sullivan
Senior Vice President
212-836-9608
dsullivan@equityny.com

Kalle Ahl, CFA
Vice President
212-836-9614
kahl@equityny.com

Original Article: (https://www.businesswire.com/news/home/20200210005690/en/)